Zeneca Data News Today

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD ...

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses ...

23.02.2024 - Positive results from the MANDARA Phase III trial for FASENRA (benralizumab) in patients with EGPA were published in the New England Journal of Medicine today,1 as the first head-to-head trial of biologics in patients with EGPA,2 and the first to ...

Yang Xu, Director of Medical Affairs for Respiratory & Immunology at AstraZeneca UK, explores whether the UK over-relies on SABA inhalers, and how we can do better to improve asthma care and treatment.

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of FASENRA to three injections per month of mepolizumab ...

Investegate announcements from AstraZeneca PLC, Update on Evusheld US EUA

RQ Bio's innovative antibody generation strives for fast impact for vulnerable patients in areas of current unmet medical and public health needFrom discovery to clinical trial in less than

Politico Studio spoke to health care professionals and patient advocacy groups about the continuing impact of COVID-19 on patients with compromised immune systems, and the actions they believe policymakers should be taking.

Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six month follow-up analysis, compared to ...